Pseudomonas aeruginosa: Epidemiology of bacteremia and antimicrobial susceptibility pattern in a teaching hospital in kuala lumpur

Journal of Health and Translational Medicine

Volumn 9, Issue 1, 2006, Pages 14-19

  Nadeem, S R ^a   Rina, K ^a,b   Hamimah, H ^a   Savithri, D P ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Antimicrobial susceptibility; Bacteremia; Pseudomonas aeruginosa

Indexed keywords

EID: 64149103223     PISSN: 18237339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Aliaga L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteremia. J Med Microbiol 2002; 51: 615-9.
2. Bodey GP, Bolivar R, Fainstein V, et al. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983; 5: 279-313.
3. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, (eds.), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th edition. Philadelphia: Churchill Livingstone; 2000. pp. 2310-35.
4. Kovacs K, Paterson DL, Yu VL. Antimicrobial therapy for Pseudomonas aeruginosa. Available at http://www.medscape.com/viewarticle/417355.
5. Foca M, Jakob K, Whittier S, et al. Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med 2000; 343: 695-700.
6. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
7. National Consensus for Clinical Laboratory Standards (NCCLS). Performance standards for Antimicrobial Disk Susceptibility Tests - Sixth Edition: 1999. Approved Standard M2-A6 NCCLS, Wayne, PA.
8. National Consensus for Clinical Laboratory Standards 2000. Performance Standards for antimicrobial susceptibility testing. Tenth informational supplement M100-S10. Wayne, PA: NCCLS.
9. Lopez Dupla M, Martinez JA, Vidal F, et al. Clinical characteristics of breakthrough bacteremia: a survey of 392 episodes. J. Intern Med 2005; 258:172-80.
10. Whitecar JP Jr, Luna M, Bodey GP. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci 1970; 260: 216-23.
11. Forkner CE Jr, Frei E 3rd, Edgcomb JH, et al. Pseudomonas septicemia; observations on twenty-three cases. Am J Med 1958; 25: 877-89.
12. Aliaga L, Mediavilla JD, Llosa J, et al. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000; 19: 871-4.
13. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-6.
14. Gallagher PG, Watanakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev Infect Dis 1989; 11: 846-52.
15. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-6.
16. Mallolas J, Gatell JM, Miro JM, et al. Epidemiological characteristics and factors influencing the outcome of Pseudomonas aeruginosa bacteremia. Rev Infect Dis 1990; 12: 718-9.
17. Mallolas J, Gatell JM, Miro JM, et al. Analysis of prognostic factors in 274 consecutive episodes of Pseudomonas aeruginosa bacteremia. Antibiot Chemother 1991; 44: 106-14.
18. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17: 701-8.